Business Context and Reporting Period
MiMedx Group, Inc. filed this Form 8-K on January 10, 2016, reporting the entry into and subsequent completion of a material definitive agreement to acquire Stability Inc. The Merger Agreement was signed on January 10, 2016, and the transaction was consummated on January 13, 2016. Upon completion, Stability ceased to exist and became a wholly-owned subsidiary of MiMedx, renamed "Stability Biologics, LLC."
Key Financial Metrics and Transaction Terms
- Initial Consideration: $10,000,000 total Closing Merger Consideration.
- Payment Structure: 60% in cash and 40% in MiMedx common stock.
- Stock Issuance: 441,009 shares of MiMedx common stock issued to Stability stockholders.
- Share Price Basis: Stock consideration valued at $9.07 per share (30-day average closing price prior to closing).
- Debt Assumption: MiMedx assumed certain outstanding indebtedness of Stability.
- Earn-Out Consideration: Additional payments based on Stability's performance through December 31, 2017.
- Formula: 1x gross profit margin on net sales of Stability products (sold by Stability/MiMedx) and MiMedx products (sold by Stability).
- Threshold: If net sales for an earn-out period are less than $12 million, the multiplier decreases to 0.5x.
- Payment Mix: Earn-out payments are also 60% cash and 40% stock.
Material Changes and Credit Agreement Amendment
On January 10, 2016, MiMedx amended its existing Credit Agreement (dated October 12, 2015) to facilitate the acquisition. Key modifications include:
- Explicit permission for the acquisition of Stability.
- Exclusion of earn-out payments and other deferred compensation payable in equity interests from the Company's leverage ratio and fixed charge coverage ratio calculations.
Outlook, Risks, and Contingencies
- Lock-Up Agreements: Stability stockholders agreed not to sell Closing Merger Shares or Earn-Out Shares for up to 12 months, with partial releases possible at six and nine months.
- Setoff Rights: MiMedx retains the right to setoff certain indemnification claims against the Earn-Out Consideration.
- Financial Reporting: Audited financial statements of Stability and pro forma financial information for the merger are not included in this filing but will be filed by amendment within 71 calendar days.
- Regulatory Disclosure: Press releases announcing the agreement and completion were issued on January 10 and January 13, 2016, respectively.
Investor Verification Checklist
- Verify the final calculation of the 40% stock component based on the specific 30-day average closing price used at closing.
- Review the upcoming 71-day amendment for Stability's audited financial statements and pro forma impact on MiMedx's balance sheet.
- Monitor the $12 million net sales threshold for the 2016 and 2017 earn-out periods to determine if the 0.5x or 1.0x multiplier applies.
- Confirm the specific amount of Stability's indebtedness assumed by MiMedx, as the exact figure is not detailed in this summary.
- Check for any future amendments regarding the release of locked-up shares prior to the 12-month mark.